Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

AstraZeneca’s Imfinzi alone and in combination fails in Stage IV lung cancer trial

pharmaceutical-technologyNovember 19, 2018

Tag: AstraZeneca , NSCLC , lung cancer , Imfinzi , tremelimumab

PharmaSources Customer Service